AFP
VYNT

Ausdal Financial Partners’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Ausdal Financial Partners’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-33
Closed -$17K – 1083
2015
Q4 		$17K Buy
+33
New +$23.8K 0.01% 781

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QGM
Quality Growth Management Rancho Santa Fe, California $88.9M AUM
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ausdal Financial Partners's VYNT Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2016, closing a stake of 33 shares — an estimated $17K sold.

Ausdal Financial Partners first reported a position in VYNT in Q4 2015 and held it in 1 quarter. The position peaked at $17K in Q4 2015. 29 funds tracked by Wall St. Rank hold VYNT as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 33 Vyant Bio, Inc. Common Stock shares in Q1 2016, an estimated $17K.
  • Ausdal Financial Partners first reported a position in Vyant Bio, Inc. Common Stock in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Vyant Bio, Inc. Common Stock position peaked at $17K in Q4 2015.
  • 29 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.